Real-World Experience with ¹⁷⁷Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.

Authors: Tuchayi, Abuzar Moradi, Yadav, Surekha, Fei Jiang, Kim, Sarasa T., Saelee, Rachelle K., Morley, Amanda, Juarez, Roxanna, Lawhn-Heath, Courtney, Yingbing Wang, de Kouchkovsky, Ivan, Hope, Thomas A.

Source: Journal of Nuclear Medicine; May2024, Vol. 65 Issue 5, p735-739, 5p